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Abstract
Studies of influenza transmission are necessary to predict the pandemic potential of emerging influenza viruses. Currently,
both ferrets and guinea pigs are used in such studies, but these species are distantly related to humans. Nonhuman
primates (NHP) share a close phylogenetic relationship with humans and may provide an enhanced means to model the
virological and immunological events in influenza virus transmission. Here, for the first time, it was demonstrated that a
human influenza virus isolate can productively infect and be transmitted between common marmosets (Callithrix jacchus), a
New World monkey species. We inoculated four marmosets with the 2009 pandemic virus A/California/07/2009 (H1N1pdm)
and housed each together with a naı¨ve cage mate. We collected bronchoalveolar lavage and nasal wash samples from all
animals at regular intervals for three weeks post-inoculation to track virus replication and sequence evolution. The
unadapted 2009 H1N1pdm virus replicated to high titers in all four index animals by 1 day post-infection. Infected animals
seroconverted and presented human-like symptoms including sneezing, nasal discharge, labored breathing, and lung
damage. Transmission occurred in one cohabitating pair. Deep sequencing detected relatively few genetic changes in
H1N1pdm viruses replicating in any infected animal. Together our data suggest that human H1N1pdm viruses require little
adaptation to replicate and cause disease in marmosets, and that these viruses can be transmitted between animals.
Marmosets may therefore be a viable model for studying influenza virus transmission.
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Introduction
Studies of influenza virus transmission, pathogenesis and
immunity rely on animal models to understand processes that
are difficult or impossible to investigate in humans. Mice, ferrets,
guinea pigs and rhesus macaques have all been used to study
various aspects of human infection with influenza viruses [1]. For
transmission studies, ferrets are a favored model system due to
their susceptibility to unadapted human influenza strains, their
development of human-like symptoms during infection and their
susceptibility to respiratory droplet transmission. However, ferrets
are evolutionarily distant from humans, and a lack of reagents
makes immunological studies difficult [2]. Nonhuman primates
(NHP) have closer immunological and physiological resemblances
to humans; a NHP model may therefore provide the closest
possible model for immunity to, and transmission of, influenza
viruses in humans. Although macaque monkeys have been used in
studies of influenza pathogenesis and immunity [1], transmission
of influenza viruses between macaques has not been documented,
and there is currently no NHP model for influenza transmission
studies. The common marmoset (Callithrix jacchus) is an attractive
potential model due to its small size and reduced dosing
requirements for potential drug and vaccine studies in comparison
to macaques. Marmosets are small New World monkeys native to
eastern Brazil that breed well in captivity and are already used as
models for other viral pathogens, including hepatitis A virus, GB
virus B, measles virus, and several hemorrhagic fever and
herpesviruses [3].
An understanding of the factors that determine transmissibility
of a virus within the human population is indispensible for making
informed predictions about the pandemic potential of emerging
influenza viruses. Although influenza virus transmission has been
studied in a number of models, several questions remain
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unanswered. The dose required to start a new infection, an
important parameter for predicting transmission rates within the
human population, is still unknown. Although a few amino acid
substitutions have been linked to transmissibility in various
influenza subtypes [4], the kinetics by which transmissible variants
arise and persist in a population remain unclear. Additionally, the
degree to which natural selection may affect transmission between
animal hosts is poorly understood. These facets of transmission
merit further study because they inform how and why certain
influenza viruses are able to emerge and cause pandemics, while
others are not. Animal models that mimic human transmission
offer a controlled way to study transmission and answer questions,
like these, that are impossible to study in humans. Development of
a system that is capable of simultaneously modeling human
transmission, pathogenesis and immunity would allow combined
studies of all of these aspects of influenza infection in a way that is
not currently feasible.
Here we sought to determine whether a human influenza A
virus could cause disease in, and be transmitted between,
marmosets. A human H1N1pdm isolate, A/California/07/2009
(CA/07/09), replicated to high titers in all inoculated animals by 1
day post-infection and, in one instance, was transmitted between
cohoused animals. Infected marmosets showed several human-like
symptoms, including sneezing, nasal discharge, labored breathing
and evidence of lung damage. Deep sequencing revealed that few,
if any, genetic changes were required for efficient replication and
transmission of this human influenza virus isolate in marmosets,
suggesting that marmosets may be viable models for future
influenza virus transmission studies.
Materials and Methods
Animal infections
Four pairs of HI-confirmed CA/07/09-naı¨ve common marmo-
sets (Callithrix jacchus) from the Wisconsin National Primate
Research Center (WNPRC) were co-housed throughout the
experiment. One animal in each pair was inoculated with 16108
plaque-forming units (PFU) of an influenza A/California/07/2009
stock virus grown on Madin-Darby canine kidney (MDCK) cells.
A total volume of 0.2 ml of virus stock was used for each animal,
with 0.1 ml delivered intratracheally, 0.02 ml inoculated to each
tonsil, 0.02 ml to each nostril, and 0.01 ml to each conjunctiva.
Bronchoalveolar lavage (BAL) and nasal wash (NW) samples were
collected from index animals on days 1, 3, 6, 9, 13 and 22 post-
inoculation. BAL and NW samples were taken from the contact
animals at the same intervals, but offset by two days such that
samples were collected on days 3, 5, 8, 11, 15, and 22 days post-
contact. Body temperatures were assessed using rectal thermom-
eters, and were recorded with body weight at each timepoint at
which BAL and NW were collected. Symptoms were monitored
each day throughout the study. All animals cleared influenza virus
infection within 3 weeks of inoculation and were returned to the
WNPRC colony.
Ethics statement
No animals were sacrificed during this study. All animals were
cared for according to a protocol approved prior to the start of the
study by the University of Wisconsin Graduate School Animal
Care and Use Committee according to guidelines set by United
States National Research Council and the Weatherall Report [5].
All study animals were anesthetized with 100 mg/ml of ketamine
for the initial inoculation and all subsequent bronchoalveolar
lavages and nasal washes. All animals were kept on a 12-hour
light/dark cycle and the study animals were co-housed in a single
room separated from the rest of the colony. Veterinary staff
provided daily health checks on all animals twice each day, and at
the end of the study, all eight study animals were returned to the
colony. Each animal was fed 20 grams of marmoset-specific diet
twice daily, and water levels were continually monitored. To
provide environmental enrichment, a nest box, wooden perches or
branches, a hanging toy, and a ladder were present in each cage,
and a foraging device was provided with the afternoon feeding at a
minimum of once per week.
HI assays
Hemagglutination inhibition (HI) assays were used to assess
antibody responses to H1N1pdm as previously described [6]. HI
assays were performed using turkey red blood cells and A/
California/07/2009 before infection and three weeks post-
infection. Values indicate reciprocal serum titer at which
hemagglutination was no longer observed.
Cytokine detection
A cytokine detection assay was used to assess T cell responses in
the study animals. The luminex assay was performed using a 96-
well flat bottom plate and a custom set of magnetic beads designed
using antibodies specific for human cytokines and chemokines
conjugated to magnetic beads from Bio-Rad (Bio-Rad, Hercules,
CA). The conjugated magnetic beads were mixed in a 0.5%
bovine serum albumin in 16PBS and were used to coat a 96-well
flat bottom plate. BAL samples collected in 16 PBS were tested
undiluted in a volume of 50 ml. A mixture of the conjugated
magnetic beads was added to the plate, which was then washed 2
times. Samples and standards were then added to the coated plate
and incubated for 30 minutes at room temperature on an orbital
shaker at 300 RPM. The plate was then washed 3 times. After the
wash, detection antibody was added to the plate and incubated at
room temperature for 30 minutes on an orbital shaker at 300
RPM. The plate was then washed 3 times. After the wash,
Streptavidin-PE was added to each well and incubated for
10 minutes at room temperature in the dark on an orbital shaker
at 300 RPM. The plate was washed 3 times and resuspended in
125 ml assay buffer (provided by Bio-Rad). Using Bio-Rad’s Bio-
Plex Pro software, each analyte was quantified by comparison to
standards provided in the kit.
Symptom assessment
We developed a scoring system to assess the severity of
respiratory tract symptoms in infected marmosets. Animals were
observed by veterinary care staff each day of the study and
symptoms were recorded. Symptoms were scored as being either
present or absent, without subjective judgment regarding varying
levels of severity. Our scoring system is as follows: development of
nasal discharge, 1 point; sneezing, 1 point; labored breathing,
3 points. Sneezing and nasal discharge are common, minor
symptoms observed in human influenza cases [7]. In contrast,
labored breathing and other signs of respiratory distress are only
usually observed in very severe human influenza infections [8–10]
and are considered much more severe clinical symptoms for which
hospitalization is often required. As such, we assigned more points
for the development of labored breathing in infected marmosets.
Scores for each day were calculated and compared at the end of
the study.
Lung pathology
Tissue damage in the respiratory tract was assessed by
quantifying total protein levels in BAL fluid, a method that has
Influenza Transmission in Marmosets
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been described previously [11]. Each BAL sample was assessed in
triplicate, in three independent experiments, using the Quick Start
Bradford Protein Assay (Bio-Rad, Hercules, CA) following the
manufacturer’s protocol. Sample protein concentrations were
calculated by interpolation to a standard curve made up of pre-
quantified dilutions of bovine serum albumin (Bio-Rad, Hercules,
CA), with optical density measured at 600 nm. Both the
microassay and standard protocols were used, depending on the
total concentration of protein in each sample. Samples that had to
be diluted for the microassay protocol were diluted in water. Total
protein levels in the BAL fluid of infected and uninfected animals
were compared using an unpaired t-test with Welch’s correction in
Prism version 6.0b for Mac (GraphPad Software, La Jolla, CA,
www.graphpad.com).
Measuring influenza virus replication
Viral replication was monitored by standard plaque assays
performed in duplicate on MDCK cells and by QRT-PCR using a
Taqman assay with the primers F: 59-GGACTGCAGCGTA-
GACGCTTT-39, R: 59-39CATCCTGTTGTATATGAGKCC-
CAT and the probe 59-6-fam- CTHAGYTATTCWRCTGGTG-
CACTTGCC-BHQ1-39. Viral RNA was isolated using the
Maxwell System (Promega, Madison WI) for Total Viral Nucleic
Acid. Viral RNA was reverse transcribed and amplified using the
Superscript III One-Step RT-PCR System (Invitrogen, Grand
Island, NY) and quantified using a LightCycler 480 (Roche,
Indianapolis, IN). Cycling conditions were as follows; 37uC for
15 min, 50uC for 30 min, 95uC for 2 min, then 50 cycles of 95uC
for 15 sec and 60uC for 1 min. Serial dilutions of a synthetic
transcript of the influenza M gene were used to prepare an internal
standard curve in each assay. The limit of detection for the assay is
100 copies/ml.
Sequencing influenza virus genomes
Viral RNA was isolated from BAL and NW samples using the
RNeasy Mini Kit (Qiagen, Germantown, MD). Single-stranded
DNA was generated with the Superscript first-strand synthesis kit
(Invitrogen, Grand Island, NY) using the UniM primer [12] bound
to the 59 and 39 terminal repeat regions and following the
manufacturer’s protocol. PCR amplification was performed using
the Phusion high-fidelity DNA polymerase kit (New England
BioLabs Inc., Ipswich, MA) with segment-specific primers
targeting the 59 and 39 terminal repeat regions. Primer sequences
are listed in Table S1 in File S1. Cycling conditions were as
follows: 98uC for 30 seconds, followed 35–40 cycles of 98uC for
15 seconds, 62uC for 15 seconds (PB2, PB1, PA, and HA genes,
58uC for NP, NA, M, and NS genes), and 72uC for 1 minute and
20 seconds, followed by a 72uC for 10 minutes and a hold at
10uC.
PCR products were purified from a 1% agarose gel using the
QIAquick Gel Extraction Kit (Qiagen, Germantown, MD)
following the manufacturer’s protocol, and quantified with the
Qubit dsDNA HS Assay kit (Invitrogen, Grand Island, NY). For
sequencing preparation, DNA was diluted in DEPC-treated water
to a concentration of 2 ng/ml. Samples were prepared for
sequencing using the Nextera DNA Sample Preparation Kit
(Illumina, San Diego, CA) according to the manufacturer’s
protocol with slight modifications. DNA concentration was re-
quantified using the Qubit dsDNA HS Assay kit and average DNA
fragment length was determined using the Agilent High Sensitivity
DNA kit and the Agilent 2100 Bioanalyzer (Agilent, Santa Clara,
CA). Prepared samples were pooled together to a total concen-
tration of 2 nM and prepared for the Illumina MiSeq following the
Illumina Sample Preparation Guide. All samples were loaded as a
6 pM library with 1% PhiX and run with a 300-cycle kit. Output
files were generated in fastq format.
Sequence data analysis
Sequence data was imported into CLC Genomics Workbench
Version 6 (CLC Bio, Denmark) for analysis. All reads were
trimmed using a quality score threshold of 0.001, which
corresponds to a Q30 score. A reference genome was compiled
by mapping the sequenced stock virus reads to A/California/07/
2009 sequences downloaded from GenBank (accession numbers
are listed in Table S2 in File S1) and extracting the consensus
sequence. The consensus sequence was generated using the
majority base at each nucleotide position, with reads required
for all regions of the gene in order to generate the consensus.
Conflicts were resolved by voting at each base, and ambiguity
nucleotides were not used. All sample reads were mapped to these
consensus reference sequences. SNPs were called in CLC
Genomics Workbench, Version 5.5.2 (CLC Bio, Denmark) using
a frequency threshold of 1%, requiring regions to have a minimum
coverage of 100 reads and a central base quality score of Q30 or
higher.
Computational Methods
The p statistic for measuring nucleotide diversity was calculated
in PoPoolation version 1.2.2 [13] using the Variance-at-position.pl
script. A minimum coverage of 100 was required for each
sequence.
Results
A human H1N1pdm influenza virus isolate replicates to
high titer and is transmitted between marmosets
At the outset of the study, we first screened animals for pre-
existing antibodies capable of recognizing H1N1pdm using
hemagglutination inhibition assays. All animals lacked detectable
antibodies capable of neutralizing the human H1N1pdm isolate
A/California/07/2009 (CA/07/09) before inoculation (Table 1).
We next inoculated one animal in each of four cohoused pairs with
16108 plaque-forming units (PFU) of CA/07/09. Bronchoalveolar
lavage (BAL) and nasal wash (NW) samples were collected at
regular intervals for three weeks post-inoculation, and viral
replication was monitored by QRT-PCR and plaque assay. The
human isolate CA/07/09 replicated to high titer in the upper and
lower respiratory tracts of all index animals (Figure 1a and 1b).
Viral RNA was detectable in BAL fluid from infected animals
between 1 and 15 days post-inoculation, and in NW fluid from 1
to 22 days post-inoculation. Standard plaque assays showed lower
titers of infectious virus in both the upper and lower respiratory
tracts and shorter shedding time (Figure S1). By three weeks post-
inoculation, all four index animals had serum antibody titers
between 40 and 160 against CA/07/09 (Table 1). In addition,
one of the contact animals, CJ1721, the cage mate of CJ1450, had
seroconverted (Table 1). Analysis of the BAL and NW samples
from CJ1721 revealed that CA/07/09 had replicated to high titer
in this animal as well, persisting from 3 to 15 days post-contact in
both the upper and lower respiratory tracts (Figure 1c). These
data indicate that the human H1N1pdm isolate was transmitted
between animals in one of four marmoset pairs.
Marmosets develop human-like symptoms during
infection with H1N1pdm virus
To monitor symptoms throughout the study, we developed a
scoring system to assess symptom onset and disease severity (see
Influenza Transmission in Marmosets
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Materials and Methods). Weight and body temperature were
recorded on days when BAL and NW samples were taken, and
symptoms were recorded daily. There was no weight loss
(Figure 2) or fever (Figure S2) associated with infection in any
animal. Interestingly, we did observe several symptoms commonly
associated with human influenza infection. All index animals
developed nasal discharge and sneezing (Table S3 in File S1).
CJ1603 showed the most severe symptoms, experiencing sneezing,
nasal discharge, and on one day, labored breathing. Symptom
scores peaked between 8 and 10 days post-inoculation in all index
animals, ranging from a score of 2 to a score of 5 (Figure 3a).
One contact animal, CJ1721, also developed sneezing and nasal
discharge on multiple days of the study, and had a single symptom
on days 7, 9, 11, and 20 (Figure 3b). We also noted a single
instance of sneezing in CJ1589, although viral RNA was
undetectable in BAL and NW fluid from this animal, and it failed
to seroconvert. No symptoms developed in the other two contact
animals. The median summed symptom score of infected animals
(index animals and CJ1721) was 4 (range = 3–11); in contrast, the
median summed score for uninfected animals was 0 (range= 0–1).
Infection with H1N1pdm virus is associated with lung
tissue damage
Respiratory tract infection can result in disruption of the
alveolar-capillary barrier, edema and leakage of serum proteins
into the lungs [11]. Cell lysis will also cause elevated protein levels
in the lungs as cytosolic proteins will be released into the
extracellular space [11]. To assess lung tissue damage in our study,
we quantified total protein present in BAL fluid. All index animals
had elevated protein levels in their BAL fluid as infection
progressed and all showed a significant increase above day 1
levels by 9 days post-inoculation (Figure 4). CJ1754 showed a
4.82-fold increase in BAL fluid protein between days 1 and 9. In
this same period CJ1603 showed a 4.79-fold increase, CJ1580 a
1.44-fold increase, and CJ1450 a 3.26-fold increase. CJ1603, the
animal with the highest overall symptom score, developed even
higher protein levels by day 13, with a 7.73-fold increase in total
protein over day 1 levels. CJ1580 showed a delay in peak protein
increase, peaking at 27 days post-inoculation with a 6.41-fold
increase. BAL fluid from the infected contact animal, CJ1721, also
showed an increase in total protein throughout infection, with
levels peaking on day 15 (2.91-fold increase over day 1 level). In
contrast, the other three contact animals all showed only minor
fluctuations in total protein levels throughout the study
(range=20.60–0.66-fold increase). All infected animals had a
peak in BAL total protein between days 9 and 27 post-
inoculation/contact and an average total protein level of
0.26 mg/ml (range= 0.05–1.03 mg/ml, standard devia-
tion= 0.23); uninfected animals had an average BAL protein level
of 0.089 mg/ml (range = 0.052–0.14 mg/ml, standard devia-
tion= 0.03; p = 0.0002, Figure S3).
Figure 1. The human influenza virus isolate A/California/07/
2009 replicates to high titers in common marmosets. Log vRNA
copy number was determined by QRT-PCR in (A) the lower respiratory
tract using bronchoalveolar lavage (BAL) and (B) in the upper
respiratory tract using nasal washes (NW). (C) Viral RNA was also
detected in the lower (solid traces) and upper (dashed traces)
respiratory tracts of one contact animal, CJ1721.
doi:10.1371/journal.pone.0078750.g001
Table 1. Anti-CA/07/09 serum antibody titers.
Animal pre-infection 21 days post-infection
CA/07/09-specific HI CA/07/09-specific HI
Index CJ1754 ,10 160
CJ1603 ,10 40
CJ1580 ,10 80
CJ1450* ,10 80
Contact CJ1721* ,10 160
CJ1684 ,10 ,10
CJ1681 20 ,10
CJ1589 ,10 ,10
Anti-CA/07/09 serum antibody titers as determined by standard HI assays using
turkey red blood cells and A/California/07/2009 virus.
*indicates transmitting pair.
doi:10.1371/journal.pone.0078750.t001
Influenza Transmission in Marmosets
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e78750
Cytokines are detectable in NW and BAL fluid
To assess immune responses to influenza infection in the
marmoset lung, we used a commercially available assay to detect
cytokines present in BAL fluid throughout infection. Reagents
validated for rhesus macaques were used to measure levels of
interleukin (IL)-17; IL-1b; IL-9; monocyte chemotattractant
protein 1 (MCP-1; also known as CCL2); macrophage inflamma-
tory protein 1b (MIP-1b; also known as CCL4); and regulated
upon activation, normal T cell expressed and secreted (RANTES;
also known as CCL5) in the lungs of all index and contact
marmosets. Although poor cross-reactivity was observed for IL-17,
IL-1b, IL-9 and MCP-1, reagents for detection of RANTES and
MIP-1b in rhesus macaques cross-reacted with marmoset
chemokines. Levels of both of these molecules peaked around
day 10 in the lungs of all infected animals (Figure S4), consistent
with the peak in frequency of activated T cells observed in the
lungs of influenza-naı¨ve macaques [14].
Low levels of within-host diversity are maintained during
H1N1pdm replication in marmosets
Although the human CA/07/09 isolate replicated to high titer
and caused symptoms in marmosets, the fact that transmission
occurred in only one pair suggested that this human virus might
not have been optimally adapted for replication and/or transmis-
sion in these animals. We therefore used deep sequencing to
characterize the entire genomes of viruses replicating in each
animal to determine whether there was evidence for adaptation of
Figure 2. Body weight did not change during the study period
in index (A) and contact (B) animals. No statistically significant
difference in body weight lost was observed between infected and
uninfected animals (unpaired t-test with Welch’s correction, p = 0.8355).
doi:10.1371/journal.pone.0078750.g002
Figure 3. Symptom scores of infected animals reflect develop-
ment of human-like symptoms. Symptoms were scored as follows:
nasal discharge, 1 point; sneezing, 1 point; labored breathing, 3 points.
Each animal was observed at least once daily throughout the
experiment; symptoms were recorded for the days shown. The graphs
show the summed symptom scores for each index (A) and contact (B)
animal on each day on which symptoms were recorded.
doi:10.1371/journal.pone.0078750.g003
Figure 4. Protein is secreted into BAL fluid as influenza
infection progresses. Bradford assay was used to detect secretion
of proteins into the lungs as an indicator of damage to lung tissue.
Values were normalized to protein levels detected on the first day BALs
were collected. Data on subsequent days are expressed as fold increase
over this baseline level; therefore negative values on this scale indicate
decreased protein concentration in BAL with respect to baseline. Blue
bars represent index animals; green bars represent contact animals.
doi:10.1371/journal.pone.0078750.g004
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CA/07/09 to marmosets. As a measure of overall within-host viral
genetic diversity, we calculated the average nucleotide diversity (p)
across each individual gene segment at every timepoint during the
study. The p statistic is commonly used to quantify population
level diversity [15]; here, it quantifies the average level of
heterogeneity at each site in the sequence and is expressed as
the average number of substitutions per nucleotide site. Since
influenza viruses have high mutation rates, they exist in infected
hosts as ‘‘swarms’’ of related, but distinct, sequences. The stock
virus used in this experiment was itself a multiply passaged
biological isolate, i.e., not produced using reverse genetics, so we
expected that the stock would contain some level of genetic
heterogeneity. We therefore first used p to quantify the level of
diversity present in the stock. The stock virus was characterized by
low levels of diversity, with p values ranging from 0.00067 to
0.0016 substitutions per site (Figure S5). p could not be calculated
for M1 or M2, due to low coverage on parts of the terminal ends of
the sequences.
If CA/07/09 had required significant adaptation to replicate in
the marmoset host, natural selection could be expected to promote
changes in overall diversity. An increase in average nucleotide
diversity in a gene segment would suggest that replication in the
new host favors a diversifying swarm of viruses, while a decrease in
average diversity could suggest that selection is favoring a subset of
fit genotypes. Viral replication within the marmoset host did not
appear to greatly alter levels of within-host diversity within the first
days after infection. Estimated p values among all gene segments
in index animals were very similar to levels observed in the stock
virus, ranging from 0.00027 to 0.0028. Similar values were
observed across the genomes of viruses replicating in the index
animals throughout the remainder of infection (Figure S5).
We next sought to determine whether transmission resulted in
major changes in the genetic diversity of the viral swarm by
calculating p for each gene segment in the index and contact
animals at the timepoints surrounding transmission. We observed
limited changes in overall nucleotide diversity in the PB1, PA, NA,
and NS genes during transmission (Figure S5), indicating that
transmission did not significantly alter the intra-host diversity of
these segments. However, we did observe slightly higher levels of
diversity in the PB2 and M1 genes from the BAL samples, and in
both the BAL and NW samples in the HA and M2 genes (Figure
S5). Following the first timepoint after transmission, diversity in
the contact animal immediately returned to levels similar to those
observed in the index animals. Overall, these data suggest that
although a subset of genes experienced a transient increase in
diversity in the contact animal immediately following transmission,
replication within and transmission between marmoset hosts did
not significantly alter diversity of CA/07/09.
Little adaptation is required for H1N1pdm replication in
marmosets
If CA/07/09 required extensive adaptation to replicate
efficiently in marmosets, one would expect adapting mutations,
whether present in the stock virus or arising de novo, to increase in
frequency in the viral population over time. Analysis of single
nucleotide polymorphism (SNP) frequencies throughout the viral
genome and throughout the course of infection revealed the
fixation of only one nonsynonymous substitution that was common
to all infected animals, which encodes an aspartate-to-glutamate
change at amino acid position 53 in the NP protein (NP D53E).
This SNP was present in the stock virus at a frequency of 46% and
rapidly rose to fixation in all index animals (Figure 5a). Similarly,
viruses replicating in the contact animal CJ1721 shortly after
transmission had a high frequency of mutations encoding NP
D53E (Figure 5b). Interestingly, there was a transient decrease in
the frequency of this SNP after transmission in CJ1721’s upper
respiratory tract, but not in the lower respiratory tract. By day 11
post-infection, more than 90% of viruses in both the upper and
lower respiratory tracts of CJ1721 encoded NP D53E (Figure 5b).
No other nonsynonymous mutations with respect to the CA/
07/09 consensus were maintained at a high frequency in every
animal. These data indicate that, with the exception of the
mutation encoding NP D53E, there were no mutations in CA/07/
09 that were consistently selected during viral replication in
marmosets. Taken together with low levels of intra-host diversity
maintained throughout replication in marmosets, our data suggest
that H1N1pdm isolated from humans can replicate in marmosets
with little adaptation.
A mixed population of high- and low-frequency variants
is transmitted
Although only one nonsynonymous mutation consistently
became fixed during replication of CA/07/09 in marmosets, we
next wanted to determine whether transmission altered the
frequency of other individual SNPs, to assess possible selection
of variants during transmission. We therefore analyzed SNPs
present in CJ1721’s virus at the first timepoint after transmission (3
days post-contact). We observed a number of nonsynonymous
Figure 5. The NP D53E mutation is rapidly fixed in all infected
animals. (A) D53E quickly rises in frequency in all index animals. (B)
D53E is transmitted to CJ1721. Frequencies in the upper and lower
respiratory tracts in CJ1721 right after transmission closely resemble
frequencies in the index animal CJ1450 at the time of transmission.
doi:10.1371/journal.pone.0078750.g005
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SNPs present at low to intermediate frequencies (1%–40%) as well
as three SNPs present at the consensus level (greater than 50%) in
viruses isolated from the BAL and NW of CJ1721 on the first day
after transmission. Because our aim was to assess any strong
signatures of selection on the viral genome during transmission, we
focused our analyses on these three mutations. First we found the
mutation encoding NP D53E, which became fixed in all animals
within 1–11 days after infection, as discussed above. This
substitution was present in CJ1721 at a frequency of 96% in the
upper respiratory tract and 76% in the lower respiratory tract, and
was maintained at a high frequency for the remainder of infection
(Figure 5b). These frequencies very closely mimic the frequencies
observed in CJ1721’s cage mate CJ1450 on day 1 post-
inoculation, in which NP D53E was present at a frequency of
99% in the NW and 80% in the BAL (Figure 6a).
The second SNP we observed in viruses isolated from CJ1721
resulted in a glutamate-to-lysine change in the PA gene at position
327 (PA E327K). This SNP was present in CJ1721 at a frequency
of 62% in the upper respiratory tract and 86% in the lung,
although its frequency declined with time and it was lost by day 13
(Figure 6a, green traces). Interestingly, this particular mutation
was only present at a low frequency in CJ1721’s cage mate,
CJ1450. On both days 1 and 3 post-contact, PA E327K was
present at a frequency of 8% in the lung of CJ1450 and was
undetectable in its upper respiratory tract (Figure 6a, blue
traces). Therefore, it appears that this transmitted viral variant
comprised only a small percentage of the viruses present in the
index animal population.
We also observed a second SNP in the PA gene of viruses
infecting CJ1721, resulting in a glutamate-to-glycine substitution
at amino acid position 18 (PA E18G). This mutation was present
at a frequency of 80% in both the upper and lower respiratory
tracts of CJ1721 on day 3 post-contact (Figure 6b, green
traces) and at frequencies of 35% in the lung and 79% in the
nasal secretions of CJ1450 (Figure 6b, blue traces). The
frequencies of both SNPs observed in the PA gene declined in
CJ1721 after transmission and were present at very low levels by
the time infection was cleared. This suggests that these amino acid
substitutions, although transmissible, may not be advantageous for
replication within the marmoset host.
If infection of CJ1721 had been founded by a single virus, or
viruses with a single favored sequence, we would expect most
mutations to be fixed shortly after transmission. Instead, both the
nasal secretions and lungs of this animal harbored viruses
containing SNPs present at intermediate and low frequencies,
ranging from 1% to 40%. This suggests that the infecting
population was comprised of a heterogeneous population of
multiple variants rather than a single variant. Taken together with
the low levels of intra-host diversity maintained in the index and
contact animals at the timepoints surrounding transmission, these
data suggest that multiple members of the source animal’s viral
population were able to start infection in the new host.
Discussion
The ability to transmit efficiently between human hosts is a
major determinant in whether a particular influenza virus can
emerge to cause a pandemic. However, the viral and host
determinants of such ‘‘transmission fitness’’ remain unclear,
hindering our ability to predict the emergence of pandemic
viruses. Current experimental models for influenza transmission
rely on small mammals that lack developed reagents for
immunology studies and are physiologically different from
humans. Although NHP models have been developed for studies
of pathogenesis and immunity, they have not yet been used to
model transmission. Here, we report for the first time that
common marmosets are susceptible to the unadapted H1N1pdm
virus CA/07/09. The virus replicated to high titer in the upper
and lower respiratory tracts of infected animals, and caused
development of human-like influenza symptoms after infection,
including nasal discharge, labored breathing and lung damage.
Infection induces antibodies targeting CA/07/09 that are
detectable in standard HI assays. Finally, high viral RNA levels,
seroconversion and appearance of symptoms were also observed in
a single contact animal, CJ1721, indicating that the human isolate
CA/07/09 was transmitted between co-housed marmosets.
Marmosets may make a suitable NHP model for influenza for a
number of reasons. Their small size (average size ranges from 400–
420 grams) translates to smaller dosing requirements for potential
vaccine and drug studies, which may increase their economy over
larger monkeys [3]. Additionally, marmosets do not harbor
Macacine herpesvirus 1 (formerly Cercopithecine herpesvirus 1; commonly
known as herpes B virus), which is endemic in Asian macaques and
can cause fatal encephalitis in humans [3]. Although marmosets
have previously been used to study other viral diseases [3], their
utility for influenza studies has never been assessed.
Figure 6. Variants present at both low and high frequencies are
transmissible. (A) PA E327K was present in less than 10% of the
viruses replicating in the index animal but was present at a high
frequency in both the lung and nasal secretions of CJ1721 shortly after
transmission. This variant frequency declined in CJ1721 after transmis-
sion. (B) PA E18G was present at a frequency around 80% in CJ1721
directly after transmission, but declined over the remainder of the
study.
doi:10.1371/journal.pone.0078750.g006
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Importantly, our study shows that marmosets share many
aspects of influenza infection that occur in humans. In a typical
human infection, virus shedding begins within the first day after
inoculation and persists for eight to nine days [7]. Symptoms
generally appear one to four days post-exposure (average is two
days), and can include fever, myalgia, malaise, sore throat, cough,
headache, sneezing, nasal discharge, and in severe cases labored
breathing and lung damage [7]. While other NHP species have
been used to study influenza immunity and pathology, they
frequently do not develop upper respiratory tract symptoms
characteristic of human infection with H1N1 or H3N2 viruses [2].
In our study, all infected marmosets developed human-like
symptoms between 5 and 8 days post-contact, indicating disease
progression similar to that observed in humans. In this study,
marmosets began shedding virus by one day post-inoculation, and
viral RNA remained detectable for between 13 and 22 days. This
represents a longer infection than what is observed in humans and
other animal hosts [7], but it is unclear whether this prolonged
shedding is a hallmark of marmoset influenza infection or is due to
the relatively high inoculum dose used for this study. For
comparison, most experimental inoculations of rhesus macaques
use between 2 and 96106 PFU [16]; human volunteer challenge
studies have inoculated between 16103 and 1.76107 PFU [7], and
ferret studies often challenge with 106 PFU [17]. We chose to use a
high inoculum dose in the present study to allow us to
unambiguously determine whether marmosets can be infected
with human influenza viruses. Although we did not determine a
minimum infectious dose in this study, we predict that future work
will find that a lower dose can be used to achieve a productive
infection.
The development of sneezing in marmosets is important.
Human influenza can be transmitted in three ways: via direct
contact, large droplets, and small aerosols. While the relative
importance of each of these modes of transmission in human cases
is not yet clear, all are known to occur, and several studies suggest
that transmission by large and small droplets is likely to be the
most efficient [18]. Sneezing generates a large number of particles
that can vary substantially in size [19]; upon expulsion into the air,
small particles can rapidly evaporate and shrink, allowing them to
float in air currents without settling for long periods of time [18].
This allows small aerosols to travel for longer distances before
settling, facilitating long-range transmission and establishment of
infection in the lower respiratory tract. Thus, the development of
sneezing in marmosets greatly enhances the likelihood that aerosol
transmission could occur. The design of our study did not allow us
to determine the mode of transmission that occurred between
CJ1450 and CJ1721. Animals were co-housed, meaning that they
shared food, water, and living space. Co-habitation can facilitate
transmission through direct contact [20], but does not exclude
large droplet or aerosol transmission. Small aerosols can be
generated from breathing alone [21], and large droplets can arise
from breathing, coughing, sneezing or speaking and travel
distances up to 3 feet [18,22]. Although transmission in our study
occurred before CJ1450 showed any symptom development
including sneezing, this does not exclude the possibility that
CJ1450 generated aerosols or large droplets through breathing or
vocalizations. Therefore, there is no way to definitively determine
how transmission occurred. Although all of the marmoset pairs
were kept in the same room, it is unlikely that transmission
occurred between CJ1721 and any index animal other than
CJ1450 because transmission occurred before any index animals
developed symptoms. The first instance of sneezing was recorded
in CJ1603 5 days post-infection; vRNA was detected in CJ1721 as
early as 3 days post-contact. Given the lack of respiratory
symptoms that could facilitate transmission before the transmission
event, it is likely that CJ1721 acquired H1N1pdm from the
marmoset with which it had the most contact, CJ1450. However,
the incidence of sneezing later in infection in all infected
marmosets suggests that marmosets may be able to model
transmission dynamics of all three modes of human transmission.
Secondary attack rate measures the rate of new disease cases
arising from contact with an infected person. Human epidemiol-
ogy studies conducted during and after the 2009 H1N1 pandemic
have used confirmed influenza-positive patients to measure
secondary attack rates for their household contacts. These
estimates range from 13%–31% [23–25], indicating that even in
humans, inter-host influenza transmission is not 100% efficient. In
contrast, the ferret and guinea pig model systems are characterized
by much higher rates of 2009pdm transmission between animals,
with some studies reporting transmission rates of 100% [26–28].
Although transmission of 2009pdm does not appear to be as
efficient in marmosets, the rates observed in our study are within
the range of estimated human transmission efficiency. Although
this study used a small sample size which limited our ability to
assess transmission efficiency in a rigorous manner, our observed
transmission rate of 25% is nonetheless within the range of
H1N1pdm secondary attack rates estimated for the human
pandemic. Should future studies uphold this relatively modest
transmission efficiency, we recognize that it could represent a
drawback to the marmoset transmission model. However, we do
not anticipate that marmosets will replace widely used transmis-
sion models like guinea pigs and ferrets. Rather, we predict that a
marmoset model could play a role in influenza transmission studies
for which guinea pigs and ferrets are currently not suited, by
providing the ability to study transmission and immunity
simultaneously in the same organism.
This study assessed immune responses to influenza infection by
assessing antibody production and using a bead array to quantify a
panel of cytokines and chemokines in BAL fluid. We detected a
peak in levels of the chemokines RANTES and MIP-1b in lungs at
10 days after infection. This timing is consistent with previously
documented peaks in the frequency of activated T cells in the
lungs of influenza-naı¨ve macaques infected with human influenza
viruses [14]. We therefore speculate that activated T cells may
have been secreting the majority of RANTES and MIP-1b in the
lungs of infected marmosets, but it is possible that T cells were not,
or not the only, sources of these chemokines. We observed limited
cross-reactivity between a set of commercial reagents for IL-17,
IL-1b, IL-9 and MCP-1 and their cognate antigens in marmosets,
despite the fact that these reagents detect macaque antigens. These
results show that cross-reactivity between available human and/or
macaque reagents and marmoset antigens cannot be assumed;
rather, each reagent will have to be validated individually.
Although validating a large number of reagents was beyond the
scope of this study, previous work has validated some additional
immunological reagents for use in marmosets [3,29–42]. As
increasing numbers of investigators choose to use marmosets for
the study of viral pathogens, the number of validated immuno-
logical reagents will likely continue to expand.
In our study, we assessed viral replication by both molecular
and culture-based methods. While QRT-PCR showed high viral
loads in all infected animals, plaque assays showed a much lower
infectious viral titer and a significantly decreased shedding time.
Although we cannot definitively account for the low titer of
infectious virus detected by plaque assays, several observations
suggest that active viral replication did indeed occur in our study.
In three of the index animals, viral RNA levels increased after the
initial inoculation in both the NW and BAL fluid, and in two of
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the index animals, viral RNA levels did not peak until 6 days post-
infection. Viral RNA rapidly increased after contact in animal
CJ1721, which was not directly inoculated. Together, these data
suggest that detection of viral RNA was the result of virus
replication, and not merely residual RNA from the initial
inoculum. The clinical upper and lower respiratory tract
symptoms present in all infected animals but absent in uninfected
contact animals also support productive influenza infection.
Sneezing, nasal discharge, labored breathing, and lung damage
would not be expected in the absence of replicating virus.
Additionally, the simultaneous increase in viral RNA levels and
the fixation of NP D53E strongly suggests viral replication. Finally,
sequencing reads showed even coverage across the full length of all
gene segments, suggesting that there were not large numbers of
defective particles in the NW and BAL fluid of infected
marmosets.
Ideally mammals used to model human influenza transmission
should be susceptible to unadapted human isolates. Our data show
that during replication in the marmoset host, low levels of diversity
were maintained across the genome in all index animals. During
viral replication, the high error rate of the influenza virus
polymerase will result in the generation of mutations each time
the genome is replicated [43]. Under conditions that present new
selection pressures, such as replication in a novel host, positive
selection may act to promote genetic diversity. High diversity can
allow the viral population to quickly adapt to new environmental
conditions by providing a wider range of genotypes for selection to
act upon. Conversely, a virus that is already fit for replication in its
host species may not require substantial adaptation to cause
productive infection in a new individual, and selection may not
play an important role in its evolution [44]. Pandemic influenza
viruses are able to cause widespread infection because they are
able to both replicate in, and transmit efficiently among, human
hosts. Marmosets are evolutionarily close to humans, and a human
pandemic isolate that has already achieved high replicative fitness
in humans may be able to readily infect and transmit in a closely
related host. In our data, the maintenance of low levels of intra-
host diversity in the infecting viral swarm and the fixation of only a
single, conservative amino acid substitution support this interpre-
tation. Together, these data suggest that the human isolate CA/
07/09 was likely already well adapted to replicate efficiently in the
marmoset host and required only minimal evolution to cause
productive infection.
Animal models can be used to study the evolution of transmitted
viral variants, which is important for understanding the molecular
determinants of transmissibility. During transmission, a bottleneck
in the viral population size can alter the diversity observed in the
new host [45]. In our study, transmission did not result in
significant changes in the overall nucleotide diversity of any gene
segments in the viral swarm, indicating that the viral population
did not undergo a strong population bottleneck after transmission
to the new host. The presence of several SNPs at intermediate
frequencies (between 1% and 40%), as opposed to a few fixed
SNPs, right after transmission in CJ1721 suggests that infection
was founded by a mixed population of viruses. Interestingly, our
data revealed three nucleotide substitutions present at a high
frequency in CJ1721 after transmission. While NP D53E was
present at strikingly similar levels in the index and contact animals,
PA E327K was present as a minor variant in the index population.
The fixation and transmission of NP D53E strongly suggests that
this amino acid change is advantageous for efficient replication
and transmission in the marmoset host. Although the functional
role of this amino acid, located in the PB2-binding domain of NP,
is unclear, NP has been implicated in host adaptation in other
model organisms [46,47]. Importantly, the transmission of both
NP D53E and PA E327K in the same pair shows that variants
present in the index population at both low and high frequencies
can be transmitted between hosts.
Together, this study demonstrates that infection with a human
2009pdm isolate results in viral replication, antibody response,
symptom development, and transmission in marmoset hosts.
Sequence analysis of the infecting viral populations suggests that
the species barrier between humans and marmosets may be
relatively low, making them a good model for human influenza
studies.
Supporting Information
Figure S1 Infectious viral titer in BAL and NW fluid
from all marmosets. Infectious viral titer was assessed by
standard plaque assay on MDCK cells.
(TIF)
Figure S2 Infection is not associated with a change in
body temperature. No statistically significant difference in
body temperature was observed in infected vs. uninfected animals
(unpaired t-test with Welch’s correction, p = 0.2398).
(TIF)
Figure S3 Total protein levels in BAL fluid of all
animals. Total protein levels in BAL fluid of index (blue bars)
and contact (green bars) animals were assessed by Bradford assay
using a bovine serum albumin (BSA) standard. Levels in infected
and uninfected animals are significantly different (unpaired t-test
with Welch’s correction, p= 0.0002).
(TIF)
Figure S4 Chemokine levels in BAL fluid of all animals.
Levels of RANTES and MIP-1b in the BAL fluid of infected
animals peaks around 10 days post-inoculation/contact. Neither
chemokines are observed in the BAL fluid of any uninfected
contact animal.
(TIF)
Figure S5 Average nucleotide diversity across the
genomes of viruses isolated from the lower respiratory
tract (BAL, panel A) and upper respiratory tract (NW,
panel B) of index and contact animals throughout the
study.
(TIF)
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